IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Immunocore Holdings plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$29.84+0.44 (+1.50%)
Close on Oct 19, 2026
- Market cap
- $1.52B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Immunocore Holdings plc revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from sale of therapies, net | $115.93M | $106.68M | $104.48M | $103.69M | $97.96M | $93.88M | $84.05M | $80.25M | $75.35M | $70.34M | – | – | 100.0% | +18.3% |
| Product revenue, net | – | – | – | – | – | – | – | $80.25M | $75.35M | $70.34M | $67.59M | $62.63M | – | – |
| Collaboration revenue | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $53.00K | $160.00K | $2.57M | $2.22M | – | – |
By region
From the segment and revenue-disaggregation notes of Immunocore's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.